Global Rheumatoid Arthritis Diagnostic Tests Market, By Test Type (Serology Test (Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide (anti-CCP), Antinuclear Antibody (ANA), Uric Acid, Other Tests), Monitoring RA Treatment Efficiency Tests (Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), Creatinine Test)), By End User (Diagnostic Laboratories, Private Laboratories, Public Laboratories, Ambulatory Surgical Centers) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,775.1 Million in 2023 and is expected to exhibit a CAGR of 5.4 % during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focused on adopting growth strategies such as partnerships, which will drive the global rheumatoid arthritis diagnostic tests market. For instance, in September 2021, Ortho Clinical Diagnostics, pure-play in vitro diagnostics (IVD) companies, announced the availability of Immediate Spin Crossmatch (ISXM) on the company’s ortho vision and ortho vision max analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions. serological test used in blood transfusions to detect ABO blood type incompatibility between donor red blood cells and recipient serum/plasma.
Global Rheumatoid Arthritis Diagnostic Tests Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of thingss from one place to another.
COVID-19 had a positive impact on the global rheumatoid arthritis diagnostic tests market..For instance, in April 2020, Siemens Healthcare GmbH, formally unveiled the RAPIDPoint 500e Blood Gas Analyzer, adding to the company's product lineup and supporting COVID-19 initiatives. This is assisting in raising the revenue for the line.
Global Rheumatoid Arthritis Diagnostic Tests Market: Key Developments
In July 2021, Beckman Coulter, is a clinical diagnostics company, announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers. Under the terms of the agreements, Quidel will continue to manufacture and supply certain components to Beckman Coulter related to the assay, and Beckman Coulter will exclusively manufacture and sell to customers the BNP assay currently sold as TRIAGE BNP by Quidel, under the brand name Access BNP.
In May 2020, Leica Microsystems, is a microscope manufacturing company in Germany, has launched Stellaris, its new flagship confocal microscopy platform, designed to significantly improve how scientists are able to capture three-dimensional images of living cells and tissues. announced the launch of STELLARIS, the company's flagship platform for its ground-breaking confocal microscope. This platform enables three-dimensional viewing of live tissues and cells. For instance, in May 2020, F. Hoffmann-La Roche Ltd. is a multinational healthcare company in switzerland announced its acquisition of Stratos Genomics. The development of diagnostic sequencing based on DNA was made possible by this acquisition. This enhanced the business's healthcare diagnosing division and raised its revenue-generating capacity.
Browse 36 Market Data Tables and 26 Figures spread through 180 Pages and in-depth TOC on “Global Rheumatoid Arthritis Diagnostic Tests Market”- Forecast to 2030, Global Rheumatoid Arthritis Diagnostic Tests Market, By Test Type (Serology Test (Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide (anti-CCP), Antinuclear Antibody (ANA), Uric Acid, Other Tests), Monitoring RA Treatment Efficiency Tests (Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), Creatinine Test)), By End User (Diagnostic Laboratories, Private Laboratories, Public Laboratories, Ambulatory Surgical Centers) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Rheumatoid Arthritis Diagnostic Tests Market :
- The global Rheumatoid Arthritis Diagnostic Tests market is expected to exhibit a CAGR of 4% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global rheumatoid arthritis diagnostic tests market.
- Among End User, the diagnostic laboratories segment is expected to hold a dominant position in the global rheumatoid arthritis diagnostic tests market during the forecast period and this is attributed to the technological advancements in the field of rheumatoid arthritis diagnostic tests. For instance, In July 2021, Neuberg Diagnostics Private Limited, Diagnodtic labrotary in India, expands its presence in India with inauguration of new lab in Keralawit advance technological equipments.
- Among region, North America is expected to be the dominant region in the global rheumatoid arthritis diagnostic tests market, owing to the key players are focusing on organic strategies start new test launch. For instance, in November 2021, Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, announced a partnership with RxParadigm, a pharmacy benefit manager company delivering transparency and restoring competitiveness to healthcare systems, to offer RxParadigm customers access to PrismRA. PrismRA is the only molecular signature blood test available in the U.S. that informs personalized treatment decisions for patients with rheumatoid arthritis (RA).
- Major players operating in the Global Rheumatoid Arthritis Diagnostic Tests Market Abbott Diagnostics (Abbott Laboratories), Labcorp ,Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Augurex Life Sciences Corp., Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB, and Thermo Fisher Scientific Inc.